ACHV - アチ―ブ・ライフ・サイエンス （Achieve Life Sciences Inc. ）

https://www.investing.com/news/pro/oncogenex-pharmaceuticals-receives-investment-bank-analyst-rating-update-3095044

Achieve Life Sciences (ACHV) shares are down 2.24% premarket on Thursday after the firm has entered into a securities purchase pact with certain institutional investors providing for…

https://www.investing.com/news/assorted/achieve-life-sciences-prices-3m-share-offering-at-550sh-432SI-3091068

Achieve Life Sciences Inc (NASDAQ: ACHV ) announced topline results from the second Phase 3 ORCA-3 trial of cytisinicline . Consistent with the previously reported Phase 3 ORCA-2 study, ORCA-3 showed a statistically significant benefit in helping people to quit smoking compared to placebo, with low rates of adverse events. The 6- and 12-week cytisinicline treatment durations demonstrated statistically significant smoking cessation on the primary and secondary efficacy analyses compared to placebo. Primary Endpoint: Subjects who received 12 weeks of … Full story available on Benzinga.com

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. Microvast Holdings, Inc. (NASDAQ: MVST ) tumbled 22.3% to $1.71 after the US Energy Department reportedly cancelled contract negotiations for a $200 million award for the company. Achieve Life Sciences, Inc. (NASDAQ: ACHV ) dropped 14.7% to $6.95 as the company reported topline results from Phase 3 ORCA-3 trial of cytisinicline. Integra LifeSciences Holdings Corporation (NASDAQ: IART ) dropped 13.5% to $43.87 after the company announced it initiated a voluntary global recall … Full story available on Benzinga.com

https://www.investing.com/news/assorted/achieve-life-sciences-announces-last-subject-last-visit-completed-in-phase-3-orca3-trial-432SI-3043853

Achieve Life Sciences, Inc. (NASDAQ:NASDAQ:ACHV) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ETCompany ParticipantsNicole Jones - Investor RelationsJohn Bencich - Chief…

Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.83 beats by $0.06.As of December 31, 2022, the company’s cash, cash equivalents, and restricted cash was…

Achieve Life Sciences (ACHV) is scheduled to announce Q4 earnings results on Thursday, March 16th, after market close.The consensus EPS Estimate is -$0.95 and the consensus Revenue…

Achieve Life Sciences (NASDAQ: ACHV ) is set to give its latest quarterly earnings report on Thursday, 2023-03-16. Here''s what investors need to know before the announcement. Analysts estimate that Achieve Life Sciences will report an earnings per share (EPS) of $-0.83. Achieve Life Sciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.76 misses by $0.07.As of December 31, 2021, the company’s cash, cash equivalents, and restricted cash was $43.1 million.

Achieve Life Sciences (NASDAQ:ACHV) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.70 (+36.9% Y/Y) and…

Achieve Life Sciences (ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate